<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106491</url>
  </required_header>
  <id_info>
    <org_study_id>CS-SCS-01-DE</org_study_id>
    <nct_id>NCT05106491</nct_id>
  </id_info>
  <brief_title>Pulse SE - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients</brief_title>
  <acronym>PulseSE</acronym>
  <official_title>Evaluating the Efficacy and Safety of the Synchronized Cardiac Support Treatment With the Icor Kit in Patients With Cardiogenic Shock - a Pivotal Study (Pulse SE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenios AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support&#xD;
      treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software&#xD;
      Version 3.2.4&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study hypothesizes that The SCS treatment with the icor kit provides sufficient&#xD;
      support for cardiocirculatory function as indicated by a significant lactate reduction 24&#xD;
      hours on SCS treatment versus before treatment start.&#xD;
&#xD;
      Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation&#xD;
      (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac&#xD;
      Support.&#xD;
&#xD;
      Synchronized Cardiac Support describes an electrocardiogram (ECG)- triggered pulsatile&#xD;
      VA-ECMO based on R-wave detection. During diastole the pump speed and thus the flow is&#xD;
      increased and during systole the pump flow is been set on a relative minimum. This provides a&#xD;
      mechanical circulatory support pulse with oxygenated blood during diastole.&#xD;
&#xD;
      The Synchronized Cardiac Support Treatment is used in a standard VA ECMO configuration by two&#xD;
      femoral single vessel cannulas. Patients following cardiac resuscitation will undergo&#xD;
      targeted temperature management 32- 36°C according to guideline.&#xD;
&#xD;
      The Duration of Treatment can be up to 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiocirculatory stabilization and end-organ perfusion</measure>
    <time_frame>up to 14 days</time_frame>
    <description>measured by the Change in Lactate Level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiocirculatory stabilization and end-organ perfusion</measure>
    <time_frame>up to 14 days</time_frame>
    <description>measured by the following parameter: Mean Arterial Pressure, Catecholamine Support, Cardiac Index, Cardiac Output and Cardiac Afterload</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintain gas exchange</measure>
    <time_frame>up to 14 days</time_frame>
    <description>measured by the following parameter: Blood Gas Analysis and Mechanical Ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracorporeal Life Support (ECLS) Performance</measure>
    <time_frame>up to 14 days</time_frame>
    <description>measured by the following parameter: Blood Flow, Blood Pressure, Synchronization of the patient's heartbeat, Intra-hospital transportation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintain renal function</measure>
    <time_frame>up to 14 days</time_frame>
    <description>measured by the following parameter: Fluid Balance, Renal Replacement Therapy, Creatinine and eGRF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thermoregulation</measure>
    <time_frame>up to 14 days</time_frame>
    <description>measured by the the Body Temperature</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Variables</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Severe adverse events, i.e. Hemolysis Bleeding&#xD;
Severe adverse device events</description>
  </other_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <condition>ECLS</condition>
  <condition>VA ECMO</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synchronized Cardiac Support with the icor kit</intervention_name>
    <description>Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).</description>
    <other_name>Synchronized Cardiac Support (icor)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent signed and dated by study patient/legal representative and&#xD;
             investigator/authorised physician&#xD;
&#xD;
          2. Minimum age of 18 years&#xD;
&#xD;
          3. Patients in cardiogenic shock&#xD;
&#xD;
          4. Cardiogenic shock is defined as:&#xD;
&#xD;
               1. Systolic blood pressure &lt; 90 mmHg for at least 30 min&#xD;
&#xD;
               2. Inotropes and/or vasopressors are needed to maintain systolic blood pressure &gt; 90&#xD;
                  mmHg&#xD;
&#xD;
               3. Clinical signs of heart insufficiency with pulmonary congestion&#xD;
&#xD;
          5. Signs of end organ hypoperfusion with at least one of the following criteria:&#xD;
&#xD;
               1. Cold, damp skin or extremities&#xD;
&#xD;
               2. Oliguria (≤ 30 mL/h)&#xD;
&#xD;
          6. Serum lactate &gt; 3.0 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In case of female patients: pregnancy or lactation period&#xD;
&#xD;
          2. Participation in an interventional clinical study during the preceding 30 days&#xD;
&#xD;
          3. Previous participation in the same study&#xD;
&#xD;
          4. Age &gt; 85 years&#xD;
&#xD;
          5. Cardiac arrest out of hospital with return of spontaneous circulation (ROSC) &gt; 30 min&#xD;
&#xD;
          6. No flow time &gt; 5 min&#xD;
&#xD;
          7. Mechanical causes for cardiogenic shock (ventricular septal defect of papillary muscle&#xD;
             rupture)&#xD;
&#xD;
          8. Non-cardiogenic causes of shock (bradycardia, sepsis, hypovolemia, etc.)&#xD;
&#xD;
          9. Fever (Body temperature &gt; 38.0 °C) or other evidence of sepsis&#xD;
&#xD;
         10. Onset of cardiogenic shock &gt; 6 h before enrolment&#xD;
&#xD;
         11. Lactate &gt; 16 mmol/L&#xD;
&#xD;
         12. Severe peripheral arterial occlusive disease precluding insertion of femoral arterial&#xD;
             or venous catheters&#xD;
&#xD;
         13. Contra-indications for anticoagulation&#xD;
&#xD;
         14. Contra-indication for VA ECMO, e.g. unrecoverable heart and not a candidate for&#xD;
             transplant or VAD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingo Voigt, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elisabeth-Krankenhaus Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Derlet-Savoia, Dr.</last_name>
    <phone>+49 6172 608 2801</phone>
    <email>anja.derlet-savoia@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celina Erfle</last_name>
    <phone>+49 6172 609 93208</phone>
    <email>celina.erfle@fmc-ag.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiogenic Shock</keyword>
  <keyword>Extracorporeal Membrane Oxygenation</keyword>
  <keyword>Synchronized Cardiac Support</keyword>
  <keyword>ECLS</keyword>
  <keyword>VA ECMO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

